Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.

Despite its excellent tolerability, using pirtobrutinib in younger, treatment-naive CLL patients is cautioned against. The short follow-up data and the potential for unique resistance mutations could prevent the subsequent use of effective covalent BTK inhibitors, ultimately shortening the patient's overall treatment options.

Obinutuzumab infusions in CLL patients can cause severe reactions. A simple and effective mitigation strategy is to pre-treat the patient with a BTK inhibitor for as little as three days before the first infusion. This debulking effect significantly reduces infusion reaction risk and improves patient safety.

Platelet aggregation studies show riluzobrutinib does not impair platelet function. This unique profile suggests it may not need to be stopped before surgery, avoiding the risk of a perilous drop in platelet counts for ITP patients—a key differentiator from other BTK inhibitors.

Pirtobrutinib is the first BTK inhibitor to show a rate of atrial fibrillation equivalent to a chemoimmunotherapy control arm in a randomized trial. This uniquely safe cardiovascular profile makes it a strong first-line candidate for older Chronic Lymphocytic Leukemia (CLL) patients or those with significant heart-related comorbidities.

Pirtobrutinib's reduced side effects, like atrial fibrillation, stem from its precise targeting of BTK with minimal 'binding promiscuity' to other kinases. This makes it a safer option for patients who have already been on a less-targeted BTK inhibitor.

While the continuous BTK inhibitor zanubrutinib showed longer progression-free survival, this efficacy came with a significant safety trade-off. It led to a 47% rate of serious adverse events compared to 24% for the fixed-duration acalabrutinib-venetoclax combination in the indirect analysis.

For older CLL patients, stopping acalabrutinib after 18 months results in relapse within a year for half of them. However, their overall survival remains identical to those who continue treatment, suggesting a "drug holiday" is a safe option for managing side effects or patient preference without long-term detriment.

BTK inhibitors block B-cell receptor signaling, causing long-surviving CLL cells to undergo programmed cell death (apoptosis) from a lack of stimulation. The common side effects are due to off-target kinase inhibition, not the intended BTK blockade itself, which has negligible action on other cells.